Last reviewed · How we verify
NCT04862468: DEXTERITY-AFP
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
Phase 2 trial testing Perivascular dexamethasone in Thrombosis, Deep Vein in 80 participants. Currently enrolling.
1 August 2026
Quick facts
| Lead sponsor | Mercator MedSystems, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 29 October 2021 |
| Primary completion | 1 August 2026 |
| Estimated completion | 1 February 2028 |
| Sites | 17 locations across United Kingdom, Ireland, United States |
Drugs / interventions tested
- Perivascular dexamethasone
- Perivascular sham
Conditions studied
- Thrombosis, Deep Vein — all drugs for Thrombosis, Deep Vein →
- Iliofemoral; Thrombosis — all drugs for Iliofemoral; Thrombosis →
Sponsor
Mercator MedSystems, Inc. — full company profile →
Who can join
Adults 18 to 89, any sex, with Thrombosis, Deep Vein or Iliofemoral; Thrombosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for up to 14 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04862468
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Perivascular dexamethasone
Trials testing the same drug.
- NCT04858776 — Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacut · Phase 2 · recruiting
Other Mercator MedSystems, Inc. trials
Trials by the same sponsor.
- NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
- NCT04858776 — Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacut · Phase 2 · recruiting
- NCT03942601 — Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropop · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04862468 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mercator MedSystems, Inc.
- Last refreshed: 4 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04862468.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing